Multiple sources report that the Trump administration dismissed the entire National Science Board (NSB), which advises the president and Congress on the National Science Foundation (NSF). The NSF’s 22 members received emails terminating their positions effective immediately on April 24, with no public explanation provided in the report. The NSB has historically influenced science and engineering priorities, while the broader NSF environment has already faced funding pressure and delays in grant processing. The removal is described as unprecedented, with lawmakers criticizing the move as disruptive to independent oversight. For biotech, changes at the NSF governance level can indirectly affect academic research funding, instrumentation development pipelines, and translational collaborations that feed early drug and platform innovation.